542 related articles for article (PubMed ID: 24830873)
1. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
Theilade S; Hansen TW; Goetze JP; Rossing P
Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
5. Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes.
Theilade S; Lajer M; Hansen TW; Rossing P
Acta Diabetol; 2014 Dec; 51(6):973-80. PubMed ID: 25274394
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
7. Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes.
Theilade S; Hansen TW; Rossing P
Am J Hypertens; 2014 Sep; 27(9):1152-9. PubMed ID: 24627444
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Drechsler C; Hayek SS; Wei C; Sever S; Genser B; Krane V; Meinitzer A; März W; Wanner C; Reiser J
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1265-1273. PubMed ID: 28495863
[TBL] [Abstract][Full Text] [Related]
10. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
11. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.
Rathcke CN; Persson F; Tarnow L; Rossing P; Vestergaard H
Diabetes Care; 2009 Feb; 32(2):323-8. PubMed ID: 18957531
[TBL] [Abstract][Full Text] [Related]
12. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
[TBL] [Abstract][Full Text] [Related]
13. suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease.
Theilade S; Rossing P; Eugen-Olsen J; Jensen JS; Jensen MT
Eur J Endocrinol; 2016 Jun; 174(6):745-53. PubMed ID: 26951602
[TBL] [Abstract][Full Text] [Related]
14. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
15. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
17. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
Rautio A; Boman K; Eriksson JW; Svensson MK
Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
[TBL] [Abstract][Full Text] [Related]
18. Urinary albumin excretion rate is independently related to autonomic neuropathy in type 2 diabetes mellitus.
Wirta OR; Pasternack AI; Mustonen JT; Laippala PJ; Reinikainen PM
J Intern Med; 1999 Apr; 245(4):329-35. PubMed ID: 10356594
[TBL] [Abstract][Full Text] [Related]
19. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
[TBL] [Abstract][Full Text] [Related]
20. Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria.
Elsamahy MH; Elhenawy YI; Nawar MM
J Diabetes Complications; 2015; 29(4):563-7. PubMed ID: 25744546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
